Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on February 26, 2018. The filing discloses the entry into a Material Definitive Agreement and the creation of a direct financial obligation. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued a promissory note to Chicago Venture Partners, L.P. (CVP) with an aggregate principal amount of $2,240,909.
- Proceeds: The aggregate purchase price was $1,560,000, reflecting an original issue discount of $655,909. The principal balance includes $25,000 to cover transaction expenses.
- Interest Rate: The Note bears interest at 8% per annum.
- Use of Proceeds: Funds are designated for general corporate purposes and working capital.
- Security: CVP received a security interest in substantially all of the Company's assets, effective upon the repayment of the existing Hercules Loan.
Material Changes and Covenants
The filing details significant new debt obligations and restrictive covenants:
- Maturity Dates: The Note matures on August 26, 2019, if the Company raises at least $12 million in equity by April 1, 2018. Otherwise, it matures on November 26, 2018.
- Repayment of Prior Debt: The Company is obligated to repay the Hercules Loan within one month of the Note's closing.
- Debt Restrictions: The Company cannot incur debt greater than $100,000 outside the ordinary course of business without CVP's consent.
- Equity Restrictions: The Company cannot issue variable securities generating less than $1 million (or the Note's outstanding balance) without consent.
- Amendment of Prior Notes: If the $12 million equity condition is met by April 1, 2018, prior notes from CVP (June 2017 and December 2017) will be amended to extend maturity to August 26, 2019, and limit monthly redemptions to $500,000.
Outlook, Risks, and Contingencies
The Company's ability to extend the maturity of this new debt and prior notes is contingent on raising $12 million in equity by April 1, 2018. Failure to meet this condition results in an earlier maturity date of November 26, 2018. The filing notes that the Company's failure to comply with covenants may subject it to liquidated damages. The transaction is subject to a subordination agreement with Hercules Capital, Inc., where CVP's debt is subordinated to Hercules' indebtedness.
Key Facts for Investor Verification
- Verify the Company's progress toward raising the $12 million equity target required to extend the debt maturity to 2019.
- Confirm the status of the repayment of the Hercules Loan, which is a condition for the security interest to become effective.
- Monitor compliance with the restrictive covenants regarding new debt issuance and variable securities.
- Review the total outstanding debt load, including the new $2.24 million note and the prior notes totaling approximately $3.74 million.